Rifaximin for Preventing Acute Graft Versus Host Disease (AGVHD)
NCT00967096
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
20
Enrollment
OTHER
Sponsor class
Conditions
Malignancy
Bone Marrow Transplantation
Interventions
DRUG:
Rifaximin
Sponsor
Emory University